×
Taysha Gene Therapies EBITDA 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Taysha Gene Therapies ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Taysha Gene Therapies EBITDA 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Taysha Gene Therapies ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$19B
Dr Reddy's Laboratories (RDY)
$12B
BridgeBio Pharma (BBIO)
$4.3B
Bausch Health Cos (BHC)
$3B
Amphastar Pharmaceuticals (AMPH)
$2.1B
Supernus Pharmaceuticals (SUPN)
$2B
Personalis (PSNL)
$261M
Assembly Biosciences (ASMB)
$98M
Sol-Gel Technologies (SLGL)
$12M
Evoke Pharma (EVOK)
$7M
Teligent (TLGT)
$0M